ChemoMetec A/S CHEMM.CO
Nasdaq Copenhagen · Healthcare · Medical Devices
706.00 DKK
+5.1%
2026-11-06
Keep this stock on your watchlist and set email alerts for prices, reports and important announcements where available.
Annual accounts for ChemoMetec
| DKK million | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | 444 | 408 | 496 | 511 |
| EBITDA | 252 | 194 | 247 | 289 |
| Net income | 179 | 136 | 175 | 202 |
| Balance sheet | ||||
| Equity | 533 | 565 | 688 | 725 |
| Total debt | 7 | 4 | 6 | 5 |
| Cash | 317 | 296 | 342 | 290 |
| Net debt | −309 | −292 | −335 | −286 |
| Ratios and per share | ||||
| EBITDA margin | 56.7% | 47.6% | 49.9% | 56.5% |
| Profit margin | 40.2% | 33.4% | 35.3% | 39.5% |
| Return on equity | 33.5% | 24.1% | 25.4% | 27.8% |
| Earnings/share (DKK) | 10.27 | 7.83 | 10.04 | 11.67 |
| Book value/share (DKK) | 30.63 | 32.48 | 39.54 | 41.94 |
| Shares outstanding (M) | 17 | 17 | 17 | 17 |
From the annual statements (Yahoo Finance), in the currency the company reports in. Per-share figures use the shares at the year end. Charts and annual figures →
Key figures
| P/E | 60.5 |
| P/B | 16.8 |
| EV / EBITDA | 41.3 |
| Net debt / EBITDA | −1.0 |
| Return on equity | 27.8% |
| Profit margin | 39.5% |
| Beta 1Y | 1.03 |
| Revenue growth 1Y | +3.1% |
| Revenue CAGR 3Y | +4.8% |
| Earnings/share CAGR 3Y | +4.4% |
| ROE avg. 3Y | 25.8% |
Ratios use the latest annual report that was public 90 days after the year end.
Dividends per share (DKK)
| 2025 | 7.00 |
| 2024 | 4.00 |
| 2023 | 6.00 |
Not investment advice. Figures may contain errors from the data source.